Bowel Cancer Combo Fails to Improve Survival (CME/CE)
(MedPage Today) — Adding the targeted therapy cetuximab (Erbitux) to a standard chemotherapy regimen in advanced colorectal cancer did not extend life, researchers reported.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com